Michael J. Daugherty & Labmd, Inc. v. Sheer

891 F.3d 386
CourtCourt of Appeals for the D.C. Circuit
DecidedJune 1, 2018
Docket17-5128
StatusPublished
Cited by16 cases

This text of 891 F.3d 386 (Michael J. Daugherty & Labmd, Inc. v. Sheer) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Michael J. Daugherty & Labmd, Inc. v. Sheer, 891 F.3d 386 (D.C. Cir. 2018).

Opinion

Wilkins, Circuit Judge:

*388 This case requires us to decide whether two Federal Trade Commission attorneys are immune from suit for their conduct during an enforcement action against a medical-records company after the company's CEO publicly criticized the FTC about their investigation, where the company's data-security practices made patient records available over public file-sharing. Because "qualified immunity protects all but the plainly incompetent or those who knowingly violate the law," Mullenix v. Luna , --- U.S. ----, 136 S.Ct. 305 , 308, 193 L.Ed.2d 255 (2015) (internal quotation marks omitted), the answer is yes. Even if the FTC attorneys sought to retaliate for the public criticism, their actions do not violate any clearly established right absent plausible allegations that their motive was the but-for cause of the Commission's enforcement action.

I.

LabMD, Inc. is a small medical-services company in Fulton County, Georgia, owned by Michael Daugherty. 1 LabMD maintained personal information about thousands of patients, including information covered by the Health Insurance Portability and Accountability Act of 1996 ("HIPAA").

In May 2008, data-security company Tiversa Holding Corporation notified LabMD that Tiversa located a LabMD PDF file with personal information about 9,300 patients on LimeWire, a peer-to-peer file-sharing application. Tiversa was able to access and download this file, known as the "1718 File," through its data-monitoring technologies that run a prodigious number of searches across file-sharing networks. Tiversa also informed LabMD that the 1718 File had "spread," meaning that other users searched for and downloaded the file on various peer-to-peer networks. LabMD determined that the 1718 File was on LimeWire because the application was installed on a LabMD billing computer, and the company removed LimeWire immediately. LabMD employees searched for the 1718 File on other networks, but did not find it. Plaintiffs-Appellees allege that Tiversa's actions were a sales tactic to attempt to persuade LabMD to purchase Tiversa's data-breach-remediation services.

Enter the FTC. On January 19, 2010, LabMD CEO Daugherty received a letter from Alain Sheer, an FTC enforcement attorney, informing LabMD that the FTC was investigating LabMD's information-security practices, because "[a]ccording to information [they] ha[d] received, a computer file (or files) from your computer network is available to users on a peer-to-peer file sharing ('P2P') network." Compl. ¶ 115. According to Plaintiffs-Appellees, Sheer knew about the 1718 File only because Tiversa contacted the FTC to suggest an investigation, another Tiversa strategy for pressuring companies to retain their services.

*389 Over the next three and a half years, FTC attorneys Sheer and Ruth Yodaiken investigated Daugherty and LabMD regarding the company's data-security practices that allowed the 1718 File to be available on LimeWire. During this period, Daugherty publicly criticized the FTC, Sheer, and Yodaiken regarding the conduct of the investigation. On September 7, 2012, the Atlanta Business Chronicle quoted Daugherty describing the FTC's investigation as "a fishing expedition" that was "beating up on small business." Compl. ¶ 128. An FTC paralegal downloaded the article and sent it to Sheer, Yodaiken, and others not named. Id. ¶ 129. Daugherty and LabMD allege that "[a]fter reading Daugherty's quote, Sheer and Yodaiken ramped up their investigative efforts against Daugherty and LabMD." Id. ¶ 130. However, it is not alleged what this "ramp[ing] up" entailed. On July 19, 2013, Daugherty posted on the internet a "trailer" for his book, The Devil Inside the Beltway , which details his experience with the FTC investigation into LabMD. Three days later, Sheer informed LabMD's attorney that the investigation team had recommended an enforcement action against LabMD to the Commission, which would make the decision about whether to bring such an action. The Commission voted unanimously to do so on August 28, 2013: the complaint against LabMD alleged that it failed to provide appropriate security for patient information, in violation of Section 5 of the Federal Trade Commission Act ("FTCA").

II.

LabMD continues to defend against the FTC enforcement action, now in federal court. LabMD also filed several cases attacking those proceedings. Each of its three lawsuits seeking to enjoin the FTC has been dismissed. See LabMD, Inc. v. FTC , No. 14-cv-810 (N.D. Ga. May 12, 2014); LabMD, Inc. v. FTC , No. 13-cv-1787 (D.D.C. Feb. 19, 2014); LabMD, Inc. v. FTC , No. 13-15267 (11th Cir. Feb. 18, 2014). This suit for damages against Sheer, Yodaiken, and another FTC attorney in their personal capacities is LabMD's fourth offensive foray in response to the FTC's enforcement effort.

Defendants moved to dismiss, and the District Court granted the motion with respect to all but the claim that the FTC attorneys Sheer and Yodaiken retaliated against LabMD and Daugherty based on Daugherty's exercise of his First Amendment rights to publicly criticize the government. See Daugherty v. Sheer , 248 F.Supp.3d 272 (D.D.C. 2017). For this particular claim, the District Court framed the allegations as "claiming that Defendants increased the intensity of the investigation in 2012 and 2013, and later in 2013 elevated the matter to an enforcement proceeding following additional public criticism by Daugherty." Id. at 285 . The District Court concluded that no special factors or alternative remedial scheme precluded a Bivens remedy for Plaintiffs-Appellees' First Amendment claims and denied Defendants' qualified-immunity defenses, reasoning that

Plaintiffs' First Amendment rights to criticize the actions of the federal government without fear of government retaliation are as clearly established as can be, and a serious escalation of an agency's investigation or enforcement against Plaintiffs for publicly criticizing the agency would appear to violate that clearly established constitutional right.

Id. at 290 .

Sheer and Yodaiken appealed. We review de novo, and "in reviewing the denial of the motion to dismiss, we take the allegations of the complaint as true." Vila , 570 F.3d at 278.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
W.D. Pennsylvania, 2026
Jones v. District of Columbia
District of Columbia, 2024
Ferris v. District of Columbia
District of Columbia, 2023
Stevenson v. District of Columbia
District of Columbia, 2022
Goodwin v. District of Columbia
District of Columbia, 2022
Ulysse v. Stokes
District of Columbia, 2021
Driever v. United States of America
District of Columbia, 2021
Gill v. United States of America
District of Columbia, 2019
Corsi v. Mueller
District of Columbia, 2019
Jonathan Capp v. County of San Diego
936 F.3d 899 (Ninth Circuit, 2019)
Phillips v. Mabus
District of Columbia, 2019
Phillips v. Spencer
390 F. Supp. 3d 136 (D.C. Circuit, 2019)
Richards v. Gelsomino
District of Columbia, 2019
Lumry v. State
Court of Appeals of Kansas, 2018

Cite This Page — Counsel Stack

Bluebook (online)
891 F.3d 386, Counsel Stack Legal Research, https://law.counselstack.com/opinion/michael-j-daugherty-labmd-inc-v-sheer-cadc-2018.